The GlycoMark test measures 1,5-anhydroglucitol (1,5-AG), which is an indicator of hyperglycemic excursions over the prior 1-2 weeks in patients with diabetes. Circulating serum levels of 1,5-AG decrease in response to significant hyperglycemia because glycosuria interferes with 1,5-AG reabsorption in the kidney tubules. Significant hyperglycemia and resultant glycosuria causes 1,5-AG levels to fall below the normal range (∼10 ug/mL), and persistent glycosuria is associated with very low 1,5-AG levels, less than or equal to 2 ug/mL. SGLT2 inhibitors elicit their effect by blocking glucose reabsorption, causing persistent glycosuria. A survey of clinical laboratory results in 2014 indicated that 13% of the GlycoMark 1,5-AG tests produced results of 2 ug/mL or less (unpublished, data on file). We hypothesized that the use of SGLT2 inhibitors (SGLT2i) would produce a high frequency of GlycoMark 1,5-AG results less than 2 ug/mL. A review of GlycoMark 1,5-AG measurements performed between January 2015 - April 2018 from 291 patients that were prescribed SGLT2i was performed. 35 patients were found to be non-compliant with their SGLT2i and were excluded from the analysis. From the remaining 256 patients taking SGLT2i, the average GlycoMark 1,5-AG level was 1.7 ug/mL and 87% of patients taking SGLT2 inhibitors had GlycoMark 1,5-AG values less than or equal to 2 ug/mL. The results of this analysis indicate that the majority of patients with diabetes that are taking SGLT2i have very low GlycoMark 1,5-AG results, which reflects the persistent glycosuria caused by the SGLT2i. In patients taking SGLT2i, a GlycoMark 1,5-AG result of 2 ug/mL may be useful as an indicator of the SGLT2i effect, particularly in patients with moderate to good glycemic control. Additionally, the average GlycoMark 1,5-AG level in the 35 non-compliant patients was 7.5 ug/mL, suggesting that GlycoMark test measurements above 2 ug/mL should be investigated for non-compliance, interference with, or reduced effectiveness of SGLT2i.


S.S. Fereidouni: Advisory Panel; Self; AstraZeneca, Janssen Pharmaceuticals, Inc. Consultant; Self; glycomark. Speaker's Bureau; Self; Amgen Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc. T.P. Shows: None. C. Lessard-Chaudoin: None. K. Brabentz: None. R.E. Tenopala: None. J.R. Dahlen: Employee; Self; GlycoMark.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at